Schrödinger, Inc. announced strong financial results for the second quarter of 2024, featuring a 35% increase in total revenue to $47.3 million. Software revenue grew by 21% to $35.4 million, and drug discovery revenue more than doubled to $11.9 million. The company is progressing its proprietary therapeutics pipeline, with initial clinical data expected from lead programs in 2025.
Total revenue increased by 35% to $47.3 million compared to Q2 2023.
Software revenue grew by 21% to $35.4 million, driven by new and existing customers and multi-year deal renewals.
Drug discovery revenue increased significantly to $11.9 million, primarily from milestone revenue from collaboration programs.
Schrödinger launched a major initiative to expand the use of computational tools for predictive toxicology, supported by a $10 million grant from the Bill & Melinda Gates Foundation.
Schrödinger updated its 2024 full-year guidance for software gross margin and operating expense growth and maintained its other financial guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance